NEW YORK (TheStreet) -- InterMune (ITMN) surged to a one-year high of $39.90 on Monday after the biotechnology company reported data on its lung disease drug pirfenidone, also known as Esbriet, that could lead to U.S. regulatory approval.
The drug is already approved in Europe to treat idiopathic pulmonary fibrosis, a disease that scars the lungs and that currently has no cure or known cause. U.S. regulators rejected the drug in 2010 and requested a new trial to determine the drug's effectiveness.
Pirfenidone and Boehringer Ingelheim's nintedanib both showed effectiveness in slowing the disease's progression. The two drugs were studied separately and were not compared to each other directly. For more on this story, read TheStreet's Adam Feuerstein's article here.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV